AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6725520 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 micrograms/kg oral clonidine
Number of subjects: 10
Study 6725520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30103220 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 981
Study 30103220 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose Azithromycin
Number of subjects: 981
Study 30103220 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose Azithromycin
Number of subjects: 981
Study 29889157 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 276
Study 27344826 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving cupping at Hechelu combined with rubbing method
Number of subjects: 216
Study 27344826 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride capsules (oral administration, once a day for 4 weeks)
Number of subjects: 216
Study 25012999 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training conducted by physical therapists in participants' homes, focusing on walking, sit-to-stand transfers, and standing, twice a week for 8 weeks.
Number of subjects: 30
Study 25012999 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 30
Study 22270977 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 59
Study 22270977 — intervention group
Group type: COMPARATOR
Intervention: Sibling support
Number of subjects: 59
Study 20484057 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/day for 6 months
Number of subjects: 99
Study 20484057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 18584574 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (2000 mg daily for 10 weeks)
Number of subjects: 20
Study 15975721 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-venous continuous renal replacement therapy (CRRT)
Number of subjects: 20
Study 15975721 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 12468480 — intervention group
Group type: EXPERIMENTAL
Intervention: Informing participants of their treatment allocation at trial closure
Number of subjects: 120
Study 12468480 — intervention group
Group type: COMPARATOR
Intervention: Not informing participants of their treatment allocation at trial closure
Number of subjects: 120
Study 12468480 — intervention group
Group type: COMPARATOR
Intervention: Reasons for not informing participants
Number of subjects: 120
Study 9799054 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole p.o. once daily for 11 days
Number of subjects: 20
Study 9799054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7617798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethanol (1.1 ml/kg 95% ethanol as a 20% solution)
Number of subjects: 12
Study 7617798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous yohimbine (0.4 mg/kg)
Number of subjects: 12
Study 7617798 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of ethanol and yohimbine
Number of subjects: 12
Study 7617798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2612797 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated erythromycin
Number of subjects: 26
Study 2612797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 325238 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (50 or 100 mg)
Number of subjects: 46
Study 325238 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine sulfate (30 or 60 mg)
Number of subjects: 46
Study 325238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31606897 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 370
Study 31606897 — intervention group
Group type: COMPARATOR
Intervention: Apixaban 5 mg twice daily
Number of subjects: 370
Study 30389745 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (not specified in detail)
Number of subjects: 143
Study 30389745 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention in children and adolescents (Maintain-Children)
Number of subjects: 143
Study 28374923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation, 2 g/day for 9 weeks
Number of subjects: 22
Study 28374923 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented group, UG)
Number of subjects: 22
Study 26001913 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised, multimodal group psychotherapy based on integrative psychotherapy (IPT)
Number of subjects: 172
Study 26001913 — intervention group
Group type: COMPARATOR
Intervention: Self-help groups
Number of subjects: 172
Study 23617452 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 30
Study 23617452 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 200 mg
Number of subjects: 30
Study 23617452 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 30
Study 23617452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21718491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) administered 4 hours prior to ischemia
Number of subjects: 23
Study 21718491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) administered 48 hours prior to ischemia
Number of subjects: 23
Study 21718491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IPC)
Number of subjects: 23
Study 19853621 — intervention group
Group type: EXPERIMENTAL
Intervention: Project STRIDE
Number of subjects: 488
Study 19853621 — intervention group
Group type: EXPERIMENTAL
Intervention: Step into Motion
Number of subjects: 488
Study 19853621 — intervention group
Group type: COMPARATOR
Intervention: Control (for STRIDE)
Number of subjects: 488
Study 19853621 — intervention group
Group type: COMPARATOR
Intervention: Control (for SIM)
Number of subjects: 488
Study 17329302 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg buspirone
Number of subjects: 60
Study 17329302 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg buspirone
Number of subjects: 60
Study 17329302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15370866 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time electromyographic feedback
Number of subjects: 28
Study 15370866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleration index delivered verbally post-lift
Number of subjects: 28
Study 15370866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback training)
Number of subjects: 28
Study 11236537 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (30 Gy in 24 fractions over 5 weeks with a pelvic boost to 50 Gy)
Number of subjects: 150
Study 11236537 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (six series of polychemotherapy with cisplatin 50 mg/m2, adriamycin 50 mg/m2, and cyclophosphamide 500 mg/m2)
Number of subjects: 150
Study 11236537 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 150
Study 11236537 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 150
Study 9308063 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N2O, 30% O2 and halothane
Number of subjects: 66
Study 9308063 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N2O, 30% O2, halothane and 2 micrograms.kg‐1 fentanyl
Number of subjects: 66
Study 9308063 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N2O, 30% O2 and 10 micrograms.kg‐1 fentanyl
Number of subjects: 66
Study 8286880 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (39 mg/day)
Number of subjects: 25
Study 8286880 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 2424279 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5,000 IU X 2 s.c.) started preoperatively and continued daily for one week post-operatively
Number of subjects: 122
Study 2424279 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-operative electrical calf muscle stimulation with groups of impulses plus post-operative dextran infusions every other day for one week
Number of subjects: 122
Study 2424279 — intervention group
Group type: COMPARATOR
Intervention: Control group (without prophylaxis)
Number of subjects: 122
Study 2424279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with intracranial neoplasms
Number of subjects: 122
Study 2424279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with intracranial vascular disease
Number of subjects: 122
Study 2424279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with spinal diagnoses
Number of subjects: 122
Study 2424279 — intervention group
Group type: EXPERIMENTAL
Intervention: Paretic lower limbs in cranial diagnoses
Number of subjects: 122
Study 2424279 — intervention group
Group type: EXPERIMENTAL
Intervention: Paretic limbs in spinal disorders
Number of subjects: 122
Study 30784726 — intervention group
Group type: EXPERIMENTAL
Intervention: Low field magnetic stimulation (LFMS) - three 20-min sessions
Number of subjects: 30
Study 30784726 — intervention group
Group type: COMPARATOR
Intervention: Sham LFMS treatment
Number of subjects: 30
Study 29509864 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening intervention
Number of subjects: 415357
Study 29509864 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (unscreened)
Number of subjects: 415357
Study 26220547 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Weeks2Freedom
Number of subjects: 3019
Study 26220547 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational film
Number of subjects: 3019
Study 26220547 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 3019
Study 23907736 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy during dental restorations
Number of subjects: 40
Study 23907736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback therapy)
Number of subjects: 40
Study 22559218 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 0
Study 20130470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 75 mg
Number of subjects: 57
Study 20130470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 150 mg
Number of subjects: 57
Study 20130470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 225 mg
Number of subjects: 57
Study 20130470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 20130470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (all doses)
Number of subjects: 57
Study 17335685 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide as maintenance therapy after double ASCT
Number of subjects: 0
Study 17335685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of conventional chemotherapy with novel agents (thalidomide or bortezomib)
Number of subjects: 0
Study 17335685 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative conditioning regimens before allogeneic stem cell transplantation
Number of subjects: 0
Study 16244539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation ON
Number of subjects: 34
Study 16244539 — intervention group
Group type: COMPARATOR
Intervention: Sacral nerve stimulation OFF
Number of subjects: 34
Study 12702936 — intervention group
Group type: EXPERIMENTAL
Intervention: GSPECT
Number of subjects: 37
Study 10825326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 30 mg IV
Number of subjects: 80
Study 10825326 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 80
Study 10825326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 10 mg IV
Number of subjects: 80
Study 10825326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 20 mg IV
Number of subjects: 80
Study 8982294 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-PCs (pooled buffy coats)
Number of subjects: 32
Study 8982294 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-PCs (single donor apheresis)
Number of subjects: 32
Study 8982294 — intervention group
Group type: COMPARATOR
Intervention: Control group (random donor platelet transfusions)
Number of subjects: 32
Study 1430132 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 treatment for 12 hours
Number of subjects: 60
Study 1430132 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 treatment for 24 hours
Number of subjects: 60
Study 1430132 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 6494068 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (six different potencies), applied once daily without occlusion
Number of subjects: 0
Study 6494068 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (six different potencies)
Number of subjects: 0
Study 2883906 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 30
Study 2883906 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 25 mg
Number of subjects: 30
Study 2883906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 20 mg
Number of subjects: 30
Study 2883906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta-adrenoreceptor antagonist)
Number of subjects: 30
Study 30160643 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic activity
Number of subjects: 347
Study 30160643 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 347
Study 30160643 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua fitness
Number of subjects: 347
Study 29237465 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete semirigid ring (SR)
Number of subjects: 171
Study 29237465 — intervention group
Group type: COMPARATOR
Intervention: Flexible band (FB)
Number of subjects: 171
Study 26169045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Number of subjects: 183
Study 26169045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 183
Study 26169045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 26169045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (AA genotype)
Number of subjects: 183
Study 26169045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (AA genotype)
Number of subjects: 183
Study 23311602 — intervention group
Group type: EXPERIMENTAL
Intervention: MEAW technique with modified Class III elastics from maxillary mini-implants
Number of subjects: 20
Study 23311602 — intervention group
Group type: COMPARATOR
Intervention: MEAW and long Class III elastics from upper second molars
Number of subjects: 20
Study 21638181 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic injection of bupivacaine
Number of subjects: 128
Study 21638181 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical wash with bupivacaine
Number of subjects: 128
Study 21638181 — intervention group
Group type: COMPARATOR
Intervention: Control (sham injection and sham wash)
Number of subjects: 128
Study 18495379 — intervention group
Group type: EXPERIMENTAL
Intervention: Non closure of the peritoneum
Number of subjects: 0
Study 18495379 — intervention group
Group type: COMPARATOR
Intervention: Closure of the peritoneum
Number of subjects: 0
Study 16510266 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) activated
Number of subjects: 4
Study 16510266 — intervention group
Group type: COMPARATOR
Intervention: Vagus nerve stimulation (VNS) de-activated
Number of subjects: 4
Study 14692130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal, epidural and general anesthesia (CSEGA)
Number of subjects: 67
Study 14692130 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 67
Study 11193132 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate aerosol (1.25 mg)
Number of subjects: 40
Study 11193132 — intervention group
Group type: COMPARATOR
Intervention: Sublingual isosorbide dinitrate tablet (5 mg)
Number of subjects: 40
Study 9196354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (half the dose)
Number of subjects: 34
Study 9196354 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (400-909 micrograms/m2/d)
Number of subjects: 34
Study 9196354 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (high doses)
Number of subjects: 34
Study 1350400 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial radiotherapy (SRT) - three fractionated doses of 150 cGy (90 kV, 5 mA, 1.00 mm aluminium filter)
Number of subjects: 0
Study 1350400 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial radiotherapy (SRT)
Number of subjects: 0
Study 1350400 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 3709993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 8
Study 30133478 — intervention group
Group type: EXPERIMENTAL
Intervention: NASVAC (therapeutic vaccine containing HBsAg and HBcAg, 100 μg each, administered in 2 cycles of 5 doses)
Number of subjects: 160
Study 30133478 — intervention group
Group type: EXPERIMENTAL
Intervention: NASVAC
Number of subjects: 160
Study 30133478 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN (48 subcutaneous injections of Peg‐IFN alfa 2b, 180 μg per dose, every week for 48 weeks)
Number of subjects: 160
Study 30133478 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN
Number of subjects: 160
Study 26728480 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV plus oral low‐dose CPA (50 mg/day)
Number of subjects: 70
Study 26728480 — intervention group
Group type: COMPARATOR
Intervention: PPV alone
Number of subjects: 70
Study 24361201 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare's nonpayment policy for catheter-associated urinary tract infections (CAUTIs) implemented in October 2008
Number of subjects: 0
Study 24361201 — intervention group
Group type: EXPERIMENTAL
Intervention: Various hospital characteristics
Number of subjects: 0
Study 22832839 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalatory/Epidural Anesthesia (IPA)
Number of subjects: 17
Study 22832839 — intervention group
Group type: COMPARATOR
Intervention: Inhalatory/Endovenous Anesthesia (IEA)
Number of subjects: 17
Study 22832839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IPA and IEA
Number of subjects: 17
Study 20658822 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nicotine patch (35 mg)
Number of subjects: 185
Study 20658822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 17854434 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for relapse prevention
Number of subjects: 302
Study 17854434 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for smoking cessation
Number of subjects: 302
Study 17854434 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 302
Study 16288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin combination treatment
Number of subjects: 383
Study 16288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine use
Number of subjects: 383
Study 16288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 383
Study 16288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated total bilirubin level
Number of subjects: 383
Study 12881158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiotomy suction
Number of subjects: 33
Study 12881158 — intervention group
Group type: COMPARATOR
Intervention: Cell-saver
Number of subjects: 33
Study 10399947 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline brca2 alterations
Number of subjects: 62
Study 10399947 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal history of breast cancer
Number of subjects: 62
Study 10399947 — intervention group
Group type: COMPARATOR
Intervention: Family history of breast/ovarian cancer or OM
Number of subjects: 62
Study 7754763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 12
Study 7754763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1970032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen-progesterone (0.05 mg ethinyloestradiol plus 1 mg norethisterone daily for 6 months)
Number of subjects: 10
Study 1970032 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 months)
Number of subjects: 10
Study 531563 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg twice daily)
Number of subjects: 18
Study 531563 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 18
Study 31868037 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented communication-input (AC-I)
Number of subjects: 62
Study 31868037 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented communication-output (AC-O)
Number of subjects: 62
Study 31868037 — intervention group
Group type: COMPARATOR
Intervention: Spoken communication (SC)
Number of subjects: 62
Study 29950824 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracopelvic assisted movement device training (12 sessions)
Number of subjects: 19
Study 26525165 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologist-led, individualised cognitive behavioural intervention (PI)
Number of subjects: 0
Study 26525165 — intervention group
Group type: COMPARATOR
Intervention: Nurse-led, minimal contact self-management condition (Control)
Number of subjects: 0
Study 22952290 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise (RE) at 40% intensity
Number of subjects: 18
Study 22952290 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise (RE) at 80% intensity
Number of subjects: 18
Study 21610207 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 (oral solution and capsule formulations)
Number of subjects: 0
Study 21610207 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 (10-150 mg single doses)
Number of subjects: 0
Study 21610207 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498
Number of subjects: 0